

CURRICULUM VITAE OF TUNDE PETO**06 December 2011****Name:** Tunde Peto, MD, MHealthEd, PhD**Current appointments:** Visiting Reader, University of Surrey
Head of Reading Centre and Medical Retina Specialist
Moorfields Eye Hospital NHS Foundation Trust
NIHR BMRC Fellow in Ophthalmology at the Institute of Ophthalmology, University College London and Moorfields Eye
Member of BMRC
Clinical Lead of the Tower Hamlets PCT Diabetic Retinopathy Screening Service, Diabetes Centre, Mile End Hospital**GRANTS ATTRACTED**

2009-2011 Hungarian Technology Grant 335 000000 forints (£100 000)

2004 - 2016 MacTel Study: £150000/year

2008 - 2010 Solvay-Quintiles Drug trial Reading Centre component £128000

2007 Nigeria Low Vision Survey Reading Centre Funding: via London School of Hygiene and Tropical Medicine Funding: £5000

2007 - 2008 Avastin in Diabetic Macular Oedema RCT Reading Centre Funding: Special Trustees of Moorfields Eye Hospital Funding

2007 - 2008 WHO Onchocerciasis Project Reading Centre Funding: WHO Funding: £50/patient

2007 Nidek Italy Automated Image Analysis Software Reading Centre Fund: NIDEK Italy Industry Funding: £3000

2007 - 2010 Kenya Eye Study Reading Centre Funding: £10000

2007 - 2009 Allergan Education Grant for Dry Eye Reading Standards Funding: £25000

2006 - 2010 IVAN RCT Reading Centre Funding: Department of Health Funding: In Excess of £100000

2004 - 2009 VPDT Cohort Study UK Funding: Department of Health: In excess of £400000

Last 3 year's referred publications

Piermarocchi S, Segato T, Scopa P, Masetto M, Ceca S, Cavarzeran F, Peto T; PAMDI Study Group. The prevalence of age-related macular degeneration in Italy (PAMDI) study: report 1. *Ophthalmic Epidemiol.* 2011 Jun;18(3):129-36.

Parmalee NL, Schubert C, Merriam JE, Allikmets K, Bird AC, Gillies MC, Peto T, Figueroa M, Friedlander M, Fruttiger M, Greenwood J, Moss SE, Smith LE, Toomes C, Inglehearn CF, Allikmets R. Analysis of candidate genes for macular telangiectasia type 2. *Mol Vis.* 2010 Dec 14;16:2718-26.

Mann SS, Rutishauser-Arnold Y, Peto T, Jenkins SA, Leung I, Xing W, Bird AC, Bunce C, Webster AR. The symmetry of phenotype between eyes of patients with early and late bilateral age-related macular degeneration (AMD). *Graefes Arch Clin Exp Ophthalmol.* 2010 Aug 25.

Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, Dowler J, Majid MA, Bailey C, Mohamed Q, Johnston R, Bunce C, Xing W; ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. *BMJ.* 2010 Jun 9;340:c2459.

- Csutak A, Lengyel I, Jonasson F, Leung I, Geirsdottir A, Xing W, Peto T. Agreement between image grading of conventional (45°) and ultra wide-angle (200°) digital images in the macula in the Reykjavik eye study. *Eye (Lond)*. 2010 Oct;24(10):1568-75.
- Michaelides M, Fraser-Bell S, Hamilton R, Kaines A, Egan C, Bunce C, Peto T, Hykin P. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1. *Retina*. 2010 May;30(5):781-6.
- Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, Boos CJ, Xing W, Egan C, Peto T, Bunce C, Leslie RD, Hykin PG. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. *Ophthalmology*. 2010 Jun;117(6):1078-1086.
- Clemons TE, Gillies MC, Chew EY, Bird AC, Peto T, Figueroa MJ, Harrington MW; MacTel Research Group. Baseline characteristics of participants in the natural history study of macular telangiectasia (MacTel) MacTel Project Report No. 2. *Ophthalmic Epidemiol*. 2010 Jan-Feb;17(1):66-73.
- Harding SP, Tomlin K, Reeves BC, Langham J, Walker J, Carpenter J, Grieve R, Patton WP, Muldrew KA, Peto T, Chakravarthy U; Verteporfin Photodynamic Therapy Cohort Study Group. Verteporfin photodynamic therapy cohort study: report 1: effectiveness and factors influencing outcomes. *Ophthalmology*. 2009 Dec;116(12):e1-8.
- Reeves BC, Langham J, Walker J, Grieve R, Chakravarthy U, Tomlin K, Carpenter J, Guerriero C, Harding SP; Verteporfin Photodynamic Therapy Cohort Study Group. Verteporfin photodynamic therapy cohort study: report 2: clinical measures of vision and health-related quality of life. *Ophthalmology*. 2009 Dec;116(12):2463-70.
- Grieve R, Guerriero C, Walker J, Tomlin K, Langham J, Harding S, Chakravarthy U, Carpenter J, Reeves BC; Verteporfin Photodynamic Therapy Cohort Study Group. Verteporfin photodynamic therapy cohort study: report 3: cost effectiveness and lessons for future evaluations. *Ophthalmology*. 2009 Dec;116(12):2471-77.e1-2.
- Sallo FB, Rechtman E, Peto T, Stanescu-Segall D, Vogt G, Bird AC, Fitzke FW. Functional aspects of drusen regression in age-related macular degeneration. *Br J Ophthalmol* 2009 Oct;93(10):1345-50.
- Schmitz-Valckenberg S, Ong EE, Rubin GS, Peto T, Tufail A, Egan CA, Bird AC, Fitzke FW. Structural and functional changes over time in MacTel patients. *Retina* 2009 Oct;29(9):1314-20
- Sallo FB, Peto T, Leung I, Xing W, Bunce C, Bird AC. The International Classification system and the progression of age-related macular degeneration. *Curr Eye Res*. 2009 Mar;34(3):238-40.